---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021516"
form_type: "8-K"
ticker: "MD"
cik: "0000893949"
company_name: "Pediatrix Medical Group, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T11:01:58.638096+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Pediatrix Q3 adjusted EPS $0.40 misses; FY2022 EBITDA guidance lowered to $240-245M

## Summary
- Adjusted EPS from continuing operations $0.40 vs $0.46 YoY; GAAP EPS $0.35.
- Net revenue $490M, down slightly from $493M YoY; same-unit revenue declined 3.2%.
- Adjusted EBITDA $58.3M, down from $73.4M YoY; FY2022 guidance $240-245M.
- CEO cites operational challenges in billing/collections and payor mix as headwinds.
- Steps underway with R1 partner to improve revenue cycle; cost cuts starting Q4.

## SEC filing metadata
- accession: 0000950170-22-021516
- form_type: 8-K
- ticker: MD
- cik: 0000893949
- company_name: Pediatrix Medical Group, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/893949/000095017022021516/0000950170-22-021516-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/893949/000095017022021516/md-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021516
- JSON: https://secwatch.observer/filing/0000950170-22-021516.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021516.txt

## Key facts
- Earnings Releases
  Pediatrix Medical Group, Inc. reported the nine months ended September 30, 2022 results: revenue $1.46 billion.
  - Period: the nine months ended September 30, 2022
  - Revenue: $1.46 billion
  - Result: reported results
  source text: For the nine months ended September 30, 2022, Pediatrix generated revenue from continuing operations of $1.46 billion, compared to $1.41 billion for the prior-year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/893949/000095017022021516/0000950170-22-021516-index.htm
- Earnings Releases
  Pediatrix Medical Group, Inc. reported the three months ended September 30, 2022 results: revenue $490 million, net income $29 million, EPS $0.35 per diluted share.
  - Period: the three months ended September 30, 2022
  - Revenue: $490 million
  - Net income: $29 million
  - EPS: $0.35 per diluted share
  - Result: reported results
  source text: Pediatrix Medical Group, Inc. (NYSE: MD) , the nation’s leading provider of highly specialized health care for women, children and babies , today reported earnings from continuing operations of $0.35 per share for the three months ended September 30, 2022. On a non-GAAP basis, Pediatrix reported Adjusted EPS from continuing operations of $0.40. For the 2022 third quarter, Pediatrix reported the following results from continuing operations: • Net revenue of $490 million; • Income from continuing operations of $29 million; and • Adjusted EBITDA of $58 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/893949/000095017022021516/0000950170-22-021516-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.